InsiderTrades.com logo
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.
Robert E. Mcnamara net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Robert Mcnamara Biography and Net Worth

Director of Axonics

Robert McNamara has served as Axonics' Audit Committee Chairman since November 2018. He is an accomplished senior executive with demonstrated success in public and privately held companies with global operations in highly competitive industries, including medical device, software and high technology. He has extensive experience in initial public offerings (IPOs), mergers and acquisitions (M&A), operations and financial management at early stage, high growth and mature companies. Mr. McNamara has raised significant capital (more than $500M) in public offerings and private placements, while managing investor relations, international operations and strategic planning. As CFO, he has managed and led three IPOs, six acquisitions/mergers, including two exceeding $1B each, and numerous rounds of venture capital funding. In 2015, he was named Acquisition International Magazine’s Texas Healthcare CFO of the Year. He has been the EVP/CFO of four public medical device companies. He is currently a member of the Board of Directors for Xtant Medical, chairs its Compensation Committee and is a member of its Audit Committee. In addition, he was elected council member and served as mayor of Menlo Park, CA.

Mr. McNamara is a CPA (nonpracticing). He has a B.S. from University of San Francisco and an M.B.A. from University of Pennsylvania’s Wharton School.

What is Robert E. Mcnamara's net worth?

The estimated net worth of Robert E. Mcnamara is at least $532,350.00 as of January 13th, 2021. Mr. Mcnamara owns 7,500 shares of Axonics stock worth more than $532,350 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Mcnamara may own. Learn More about Robert E. Mcnamara's net worth.

How do I contact Robert E. Mcnamara?

The corporate mailing address for Mr. Mcnamara and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Robert E. Mcnamara's contact information.

Has Robert E. Mcnamara been buying or selling shares of Axonics?

Robert E. Mcnamara has not been actively trading shares of Axonics during the past quarter. Most recently, Robert E. Mcnamara sold 9,167 shares of the business's stock in a transaction on Wednesday, January 13th. The shares were sold at an average price of $51.83, for a transaction totalling $475,125.61. Following the completion of the sale, the director now directly owns 7,500 shares of the company's stock, valued at $388,725. Learn More on Robert E. Mcnamara's trading history.

Who are Axonics' active insiders?

Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.

Are insiders buying or selling shares of Axonics?

During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.

Information on this page was last updated on 10/2/2024.

Robert E. Mcnamara Insider Trading History at Axonics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2021Sell9,167$51.83$475,125.617,500View SEC Filing Icon  
See Full Table

Robert E. Mcnamara Buying and Selling Activity at Axonics

This chart shows Robert E Mcnamara's buying and selling at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axonics Company Overview

Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.98
Low: $70.98
High: $70.98

50 Day Range

MA: $70.00
Low: $68.70
High: $70.98

2 Week Range

Now: $70.98
Low: $55.09
High: $71.05

Volume

N/A

Average Volume

571,295 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.